<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02877979</url>
  </required_header>
  <id_info>
    <org_study_id>IPM 042</org_study_id>
    <nct_id>NCT02877979</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety &amp; Assess Local and Systemic PK of DS003 Vaginal Tablets Administered to Healthy HIV-negative Women</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled, Dose Escalation Trial to Evaluate the Safety and to Assess Local and Systemic Pharmacokinetics of DS003 Vaginal Tablets Administered to Healthy HIV-negative Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, randomised, placebo-controlled, dose escalation trial to evaluate the safety&#xD;
      and to assess local and systemic pharmacokinetics of ds003 vaginal tablets administered to&#xD;
      healthy HIV-negative women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2015</start_date>
  <completion_date type="Actual">August 26, 2016</completion_date>
  <primary_completion_date type="Actual">August 26, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of three escalating doses of DS003 (1 mg, 3 mg and 10 mg), administered in a vaginal tablet formulation, to healthy, HIV-negative female volunteers.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Gynaecological assessments, including pelvic examination and colposcopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the local (vaginal fluids) and systemic (plasma) DS003 PK profile and the 24 hour cervical tissue concentration when administered in three escalating doses of a vaginal tablet formulation.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measurement of DS003 concentrations in plasma, vaginal fluids and cervical tissue collected at various time points after administration of the vaginal tablet(s).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>DS003 vaginal tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS003 vaginal tablet</intervention_name>
    <description>The trial will be conducted in three cohorts of 12 women each. In each cohort, participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17. In each cohort, therefore, 9 participants will receive DS003 vaginal tablets and 3 participants will receive placebo vaginal tablets.</description>
    <arm_group_label>DS003 vaginal tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Women must meet all of the following criteria to be eligible for enrolment:&#xD;
&#xD;
          1. Women ≥ 18 and ≤ 45 years of age who can give written informed consent&#xD;
&#xD;
          2. BMI of ≥ 18 and &lt; 30 kg/m2&#xD;
&#xD;
          3. Vital signs within normal limits and no clinically significant ECG findings&#xD;
&#xD;
          4. Available for all visits and consent to follow all procedures scheduled for the trial&#xD;
&#xD;
          5. Healthy, based on medical history, vital signs, physical examination, urinalysis&#xD;
             (dipstick and microscopy), laboratory evaluations for genital infections (bacterial&#xD;
             vaginosis, gonorrhoea, chlamydia and trichomonas) and laboratory evaluations for&#xD;
             haematology and biochemistry&#xD;
&#xD;
          6. HIV-negative as determined by an HIV test at the time of screening&#xD;
&#xD;
          7. On a stable form of contraception, defined as:&#xD;
&#xD;
               -  A stable oral contraceptive regimen for at least 2 months prior to enrolment, OR&#xD;
&#xD;
               -  Transdermal contraceptive patch for at least 3 months prior to enrolment, OR&#xD;
&#xD;
               -  Subcutaneous implant inserted at least 3 months prior to enrolment, OR&#xD;
&#xD;
               -  Long-acting progestins for at least 2 consecutive injections, OR An IUD inserted&#xD;
                  (with no vaginal or gynaecological complaints associated with its use) at least 3&#xD;
                  months prior to enrolment, OR&#xD;
&#xD;
               -  Have undergone surgical sterilisation at least 3 months prior to enrolment AND be&#xD;
                  willing to use oral contraceptives if necessary to delay menstruation while&#xD;
                  taking part in the trial&#xD;
&#xD;
          8. Upon pelvic examination and colposcopy at screening and visual inspection of the&#xD;
             cervix at the time of enrolment, the cervix and vagina appear normal as determined by&#xD;
             the Investigator&#xD;
&#xD;
          9. Asymptomatic for urogenital infections at the time of screening (if a woman is&#xD;
             diagnosed with any curable STI, either clinically or by laboratory test at the time of&#xD;
             screening, she must complete the full course of treatment and have a healthy genital&#xD;
             tract before being considered for potential re-screening)&#xD;
&#xD;
         10. Willing to refrain from the use of topical vaginal medications, vaginal products or&#xD;
             objects, including tampons, female condoms, cotton wool, rags, diaphragms, cervical&#xD;
             caps (or any other vaginal barrier method), douches, lubricants, vibrators/dildos, and&#xD;
             drying agents for 7 days prior to enrolment and for the duration of the trial&#xD;
&#xD;
         11. Documentation of no abnormality on cervical cytology, including grossly bloody smear,&#xD;
             within 90 days prior to screening&#xD;
&#xD;
         12. Willing to refrain from participation in any other research trial for the duration of&#xD;
             this trial&#xD;
&#xD;
         13. Willing to provide adequate locator information for trial retention purposes and be&#xD;
             reachable per local standard procedures, e.g. by home visit or telephone, or via&#xD;
             family or close neighbour contacts (confidentiality to be maintained)&#xD;
&#xD;
         14. Willing to agree to abstain from all the following for a total of 2 days (48 hours)&#xD;
             prior to each trial visit, and for a total of 3 days (72 hours) after the biopsy&#xD;
             procedure:&#xD;
&#xD;
             Penile-vaginal intercourse&#xD;
&#xD;
             • Oral contact with her genitalia&#xD;
&#xD;
         15. Hepatitis B and C negative at the time of screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Women who meet any of the exclusion criteria below are not eligible:&#xD;
&#xD;
          1. Currently pregnant or had their last pregnancy outcome within 3 months prior to&#xD;
             screening&#xD;
&#xD;
          2. Currently breast-feeding&#xD;
&#xD;
          3. Currently or within 2 months of participation in any other clinical research trial&#xD;
             involving investigational or marketed products prior to screening&#xD;
&#xD;
          4. Untreated symptomatic urogenital infections, e.g. urinary tract or other sexually&#xD;
             transmitted infections, or other gynaecological conditions such as vaginal itching,&#xD;
             pain, or discharge, prior to enrolment&#xD;
&#xD;
          5. Have a Grade 2 or higher pelvic examination finding, according to the DAIDS Table for&#xD;
             Grading the Severity of Adult and Pediatric Adverse Events; Addendum 1 Female Genital&#xD;
             Grading Table for Use in Microbicide Studies&#xD;
&#xD;
          6. History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding,&#xD;
             urethral obstruction, incontinence or urge incontinence&#xD;
&#xD;
          7. Current vulvar or vaginal symptoms/abnormalities that could influence the trial&#xD;
             results&#xD;
&#xD;
          8. Cervical cytology at screening that requires cryotherapy, biopsy, treatment, or&#xD;
             further evaluation&#xD;
&#xD;
          9. Symptomatic genital herpes simplex virus (HSV) infection or a history of genital&#xD;
             herpetic infection&#xD;
&#xD;
         10. Any Grade 2, 3 or 4 haematology, biochemistry or urinalysis laboratory abnormality at&#xD;
             baseline (screening) according to the current version of the DAIDS Table for Grading&#xD;
             the Severity of Adult and Pediatric Adverse Events&#xD;
&#xD;
         11. Unexplained, abnormal bleeding per vagina during or following vaginal intercourse, or&#xD;
             gynaecologic surgery within 90 days prior to enrolment&#xD;
&#xD;
         12. Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of&#xD;
             sensitivity/allergy to latex&#xD;
&#xD;
         13. Any serious acute, chronic or progressive disease (e.g. any known history of neoplasm,&#xD;
             cancer, diabetes, epilepsy, cardiac disease, autoimmune disease, HIV, AIDS, or blood&#xD;
             dyscrasias), or signs of cardiac disease, renal failure, or severe malnutrition&#xD;
&#xD;
         14. Have undergone a hysterectomy&#xD;
&#xD;
         15. History of drug or substance abuse within 1 year of enrolment&#xD;
&#xD;
         16. Use of tobacco within 6 months of enrolment&#xD;
&#xD;
         17. Not willing to abstain from alcohol from 14 days prior to enrolment until completion&#xD;
             of trial participation&#xD;
&#xD;
         18. Have had significant blood loss, or have donated or received one or more units of&#xD;
             blood within 6 weeks prior to enrolment&#xD;
&#xD;
         19. Have a positive urine drug or positive breath alcohol screen at screening or enrolment&#xD;
&#xD;
         20. Any disease or condition (medical or surgical) that might compromise haematological,&#xD;
             cardiovascular, pulmonary, renal, gastrointestinal, or central nervous system&#xD;
             function; or any other conditions that might interfere with the absorption,&#xD;
             distribution, metabolism, or excretion of the investigational product, or that would&#xD;
             place the participant at increased risk, as determined by the Investigator&#xD;
&#xD;
         21. Regular use of, or have received, any concomitant prescription, over-the-counter, or&#xD;
             herbal medications or nutritional supplements within 14 days prior to enrolment&#xD;
&#xD;
         22. Any condition(s) that, in the opinion of the Investigator, might interfere with&#xD;
             adherence to trial requirements or evaluation of the trial objectives&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>August 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

